ACC-001

BIOLOGICAL5 trials

Sponsors

Pfizer

Conditions

Alzheimer DiseaseAlzheimer's Disease

Phase 2

Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease

CompletedNCT00479557

PfizerAlzheimer Disease

Start: 2007-05-31End: 2013-01-31Updated: 2016-01-01

Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease

CompletedNCT00498602

PfizerAlzheimer Disease

Start: 2007-11-30End: 2013-02-28Updated: 2016-01-01

Study Evaluating ACC-001 in Japanese Patients With Mild To Moderate Alzheimer's Disease

CompletedNCT00752232

PfizerAlzheimer Disease

Start: 2008-12-31End: 2012-07-31Updated: 2016-01-01

Safety, Tolerability, And Immunogenicity Study Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease

CompletedNCT00959192

PfizerAlzheimer's Disease

Start: 2009-08-31End: 2013-01-31Updated: 2016-01-01

Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease

TerminatedNCT01238991

PfizerAlzheimer's Disease

Start: 2010-12-31End: 2013-12-31Updated: 2014-12-22